Phase 2/3 registration study of VT1021 in newly diagnosed and recurrent GBM patients
Latest Information Update: 20 Nov 2021
At a glance
- Drugs VT-1021 (Primary)
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- 09 Nov 2021 According to a Vigeo Therapeutics media release, the company expect to initiate this study in the first half of 2022.
- 24 Sep 2021 New trial record
- 21 Sep 2021 According to a Vigeo Therapeutics media release, the company expect to initiate this study by the end of 2021.